Table 1.
Wound healing response to injury | Wound healing response to Cancer | ||||
---|---|---|---|---|---|
Functions | Mechanisms | Functions | Mechanisms | ||
Blood clotting Anti-bacterial | MSCs promote blood clotting MSCs are self-defending by elimination of the invading bacteria | TFs; FVIII Secretion of anti-microbial peptides LL-37, hepcidin, (β-defensin 2 and lipocalin-2 etc. | Not known It is unclear whether the tumor-suppressive effects of MSCs are related to such a self-defending capacity by MSCs |
||
Inflammation | Myeloid cell recruitment | MSCs drive myeloid cell migration from BM to inflamed tissues | Chemokines CCL-2, CCL-3, CCL-4, CXCL1, IL-8, MIF; adhesion molecules ICAM-1, etc. | TA-MSCs recruit monocytes, macrophages and neutrophils to the tumor microenvironment | Chemokines and cytokines CCL-2, CCL-7, CCL-12, CXCL1, CXCL2, CSF1 etc. |
Myeloid cell and other innate immune cell suppression | MSCs suppress myeloid cell functions upon stimulation by TNFα, IL-1 and ROS | COX-2, PGE2, TSG-6, SOD3, etc. | TA-MSCs polarize the M1 macrophages to an M2 phenotype; TA-MSCs also stimulate MDSC differentiation | CXCL3, HGF etc. | |
Myeloid cell reprogramming | MSCs convert M1 macrophages to an M2-like type | PGE2, TSG-6, etc. | |||
T cell recruitment | MSCs augment T-cell infiltration and activities in a low-level inflammatory environment | Chemokines CXCL9, 10, 11; adhesion molecules ICAM-1, VCAM-1 | Not known | ||
T cell suppression | MSCs exert a robust suppression of T-cells upon stimulation by IFNγ together with other inflammatory cytokines | NO, IDO, PGE2, PD-L1, HO-1, LIF, IL-6, galectin 1, FasL, TGFβ, Treg, etc. | MSCs suppress anti-tumor immunity | NO, IDO, Treg, regulatory CD8+ T cells, etc. | |
Wound healing response to injury | Wound healing response to Cancer | ||||
Functions | Mechanisms | Functions | Mechanisms | ||
Proliferation | MSC homing | MSCs efficiently home to tissue injurysites | Chemokines CXCL12, CCL-2, CCL27 and CCL21; VCAM-1; MMPs; etc. | Exogenously implanted and endogenous MSCs efficiently migrate into the tumor environment | CXCL12, CCL-2, CCL-25, CXCL16, MIF, IL-6, LL-37 etc. |
MSC differentiation and fibroplasia | MSCs can be differentiated into osteoblasts, adipocytes and myofibroblasts at the injury sites | TGFβ, BMPs, Notch, Wnt, Hedgehogs, etc. | BM-MSCs or adjacent tissue-derived MSCs give rise to distinct types of tumor-associated myofibroblasts | TGFβ etc. | |
Re-epithelialization | MSCs promote epithelial cell growth | Growth factors EGF, HGF, KGF, PDGF, IGF etc. | TA-MSCs support survival of cancer stem cells and proliferation of tumor cells | IL-6, IL-8, CXCL1, CXCL7, BMPs, miRNAs | |
Angiogenesis | MSCs enhance angiogenesis | Pro-angiogenic factors VEGF, FGF, PDGF, TGFβ, etc. | TA-MSCs facilitate tumor-associated angiogenesis | VEGF, IL-6, etc. | |
Tissue remodeling | Inhibition of proliferation | MSCs inhibit tissue cell proliferation | TGFβ, cell-cell contact, MMPs | TA-MSCs suppress epithelial tumor growth but drive them to enter dormancy | TRAIL, DKK-3, cell-cell contact, cannibalization, miR-23b, 127, 197, 222, 223 |
Inhibition of angiogenesis | MSCs suppress angiogenesis during tissue remodeling | TIMPs, MMPs | TA-MSCs can inhibit angiogenesis | ROS, inhibition of PDGF signaling | |
Collagen rearrangement | MSCs promote ECM remodeling | MMPs, TIMPs, TGFβ | TA-MSCs modulate collagen organization | DDR2, MMPs | |
Tissue cell invasion | MSCs stimulate tissue cell invasion | MMPs, collagen rearrangement | TA-MSCs accelerate tumor cell invasion and metastasis | Chemokines CCL-2, CCL-5, CCL-9, CXCL10 etc.; TA-MSCs-induced EMT |
Abbreviations: TFs, Tissue factors; FVIII, Factor VIII; MIF, Macrophage migration inhibitory factor; ICAM-1, Intercellular adhesion molecule 1; CCL, CC motif chemokine ligand; CXCL, C-X-C motif chemokine ligand; IL, Interleukin; CSF1, Colony stimulating factor 1; COX-2, Cyclooxygenase-2; PGE2, Prostaglandin E2; TSG-6, Tumor necrosis factor (TNF)-stimulated gene-6; SOD3, Superoxide dismutase 3; HGF, Hepatocyte growth factor; VCAM-1, Vascular cell adhesion molecule 1; NO, Nitric oxide; IDO, Indoleamine 2,3-dioxygenase; PD-L1, Programmed death-ligand 1; HO-1, Heme oxygenase 1; LIF, Leukemia inhibitory factor; FasL, Fas ligand; Treg, Regulatory T cell; EGF, Epidermal growth factor; KGF, Keratinocyte growth factor; PDGF, Platelet-derived growth factor; IGF, Insulin-like growth factor; BMP, Bone morphogenetic protein; miRNA, microRNA; VEGF, Vascular endothelial growth factor; FGF, Fibroblast growth factors; PDGF, Platelet-derived growth factor; TGFβ, Transforming growth factor beta; MMP, Matrix metalloproteinase; TRAIL, TNF-related apoptosis-inducing ligand; DKK-3, Dickkopf WNT Signaling Pathway Inhibitor 3; TIMP, Tissue inhibitor of metalloproteinase; ROS, Reactive oxygen species; DDR2, Discoidin domain receptor 2; EMT, Epithelial–mesenchymal transition.